ERBB2 and breast carcinoma: They have also demonstrated that BTG2 suppresses the activation of the HER2 pathway and suggested that HER pathway inhibitors, such as lapatinib, may play a role in controlling the progression of disease among breast cancers with decreased BTG2 expression.